A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.

Key facts

Study ID

NCT06602219

Run by

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

People needed

222

Starts

2024-10-25

Expected to finish

2025-09-04

Last updated by the study team

2025-09-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization
• Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).
• Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.
• Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study

You may not qualify if…

• Have had a clinically significant flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator.
• Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.
• Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.
• Have a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics).
• Have a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.

Where it is running

• Dermatology Trial Associates — Bryant, Arkansas, United States
• Zenith Research, Inc. — Beverly Hills, California, United States
• First OC Dermatology Research Inc — Fountain Valley, California, United States
• Center for Dermatology Clinical Research — Fremont, California, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Driven Research — Coral Gables, Florida, United States
• Direct Helpers Research Center — Hialeah, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• GCP Global Clinical Professionals, LLC — St. Petersburg, Florida, United States
• ForCare Clinical Research — Tampa, Florida, United States
• Endeavor Clinical Trials Center - Dermatology - Skokie — Skokie, Illinois, United States
• Lawrence J Green, M.D, LLC — Rockville, Maryland, United States
• Center for Clinical Studies, LTD.LLP — Webster, Texas, United States
• Interior Dermatology Centre - Probity - PPDS — Kelowna, British Columbia, Canada
• Skin Care West — Nanaimo, British Columbia, Canada
• Simcoderm Medical & Surgical Dermatology Centre — Barrie, Ontario, Canada
• Dermatrials Research Inc. — Hamilton, Ontario, Canada
• Lovegrove Dermatology - Probity - PPDS — London, Ontario, Canada
• DermEffects - Probity - PPDS — London, Ontario, Canada
• Lynderm Research Inc. — Markham, Ontario, Canada
• DermEdge Research — Mississauga, Ontario, Canada
• Clintrial s.r.o. — Prague, Praha 10, Czechia
• Pratia Pardubice a.s. - PRATIA - PPDS — Pardubice, Czechia
• Cahaba Dermatology Skin Health Center — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.